MRD / Regn No. : 20250000677 Date : 09/06/2026
Patient Name : Rita Mahato Age & Gender : 45 Yrs. / Female
Contact No. : 993258600 UHID :
Ht / Wt / BMI : 156 / 63 / 25.89 BP S / BP D : 10376 /
Allergies : NKA Referred By :
   
Problem List : TYPE 2 DM (03/Sep/2025) | DYSLIPIDEMIA (04/Sep/2025) | OBESITY (04/Sep/2020) |
Subjective : NEW ONSET DM,HAS STOPPED STATIN
Objective : NONE
Analysis : TYPE 2 DM,OBESITY,DYSLIPIDEMIA
Plan : REDUCE SEMAGLUTIDE 3 MG,ADD SGLT2I,SEE ME IN 2 MONTHS WITH TESTING  
Salient Investigations : FASTING PLASMA GLUCOSE (FPG): 113 mg/dL | GLYCOSYLATED HEMOGLOBIN (HBA1C): 6.6 % | POST PRANDIAL GLUCOSE (2HPP): 100 mg/dL
S# Generic (Trade) Name Route Dosage Usage Duration
1 TABLET SEMAGLUTIDE 3 MG
RYBELSUS
Medicine For DIABETES OBESITY 		PO 1-0-0 BEFORE FOOD
 TILL NEXT VISIT
TAKE SEMAGLUTIDE IN AN EMPTY STOMACH WITH 120 ML W...
2 SGLT2I EMPAGLIFLOZIN 10 MG
JARDIANCE
Medicine For DIABETES OBESITY HEART AND KIDNEY PROTECTION 		PO 1-0-0 BEFORE FOOD
 TILL NEXT VISIT
MAY CAUSE GENITOURINARY INFECTIONS
       
Refill : 0 / Substitution:    
Education :
Next Visit : 08/Aug/2026
Tests Suggested For Next Visit : FBS 2HPP
   
   

Dr. Krishna G Seshadri
Sr. Consultant Endocrinology Diabetes and Metabolism
Tamil Nadu / 48748 HPRID: 71-0638-2075-7542

Disclaimer: This is an ONLINE consultation. The patient has not been physically examined. The prescription or advice is based on the patient's description of the problem which is given above and also explained over video consultation.
This is a Computer generated Prescription

Powered By: